ECWM-R3

Study Design: Phase II, single arm, multicenter, French trial for treatment naive WM patients

Patients: relapsed WM patients

Treatment: Idelalisib-Obinutuzumab

Status of the Study: completed, published (C Tomowiak, Blood Adv. 2021)

Sponsor: Tour, France

further information